Airgain (AIRG) Q4 2024 Earnings Call February 28, 2025 12:36 AM ET Company Participants Jacob Suen - Chief Executive OfficerMichael Elbaz - CFO & Secretary Conference Call Participants Anthony Stoss - AnalystTim Savageaux - MD & Senior Research Analyst Operator Good afternoon. Welcome to Airgain's Fourth Quarter and Full Year twenty twenty four Conference Call. My name is Julian, and I'll be operator for today's call. Joining us today are Airgain's President and CEO, Jacob Soon and CFO, Michael Alves. As a ...

Imunon (IMNN) Q4 2024 Earnings Call February 28, 2025 12:33 AM ET Company Participants Peter Vozzo - Managing DirectorStacy Lindborg - President, CEO & DirectorDouglas Faller - Chief Medical OfficerDavid Gaiero - Chief Financial OfficerJoey Brusca - Equity Research AssociateKhursheed Anwer - Executive VP & Chief Scientific OfficerJason Kolbert - Managing Director Conference Call Participants David Bautz - Senior AnalystJames Molloy - Managing Director, Senior Biotechnology & Specialty Pharmaceuticals Equity ...

Rimini Street, Inc. (NASDAQ:RMNI) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dean Pohl - Vice President, Treasurer and Investor Relations Seth Ravin - CEO, President & Chairman of the Board Michael Perica - EVP & Chief Financial Officer Conference Call Participants Brian Kinstlinger - AGP Jared Jungjohann - TD Cowen Jeff Van Rhee - Craig-Hallum Richard Baldry - ROTH Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Rimini Street Q4 2024 Earning ...

Financial Data and Key Metrics Changes - The company reported a revenue of almost $29 million for the year, a decrease from approximately $38 million in 2023, primarily due to a shift towards internal and co-development programs [37] - Research and development expenses were approximately $167 million, down $8 million from the previous year, reflecting a one-time payment of about $32 million made in 2023 [38] - The net loss for the year was roughly $163 million, compared to a loss of about $146 million the previous year, which included non-cash impairment charges for in-process R&D of approximately $47 million [39] Business Line Data and Key Metrics Changes - The company has a cumulative total of 96 partner-initiated programs with downstream participation, with 14 programs still actively led or co-led by the company [30][33] - The company initiated two new partnerships in the first half of 2024 and expanded one existing collaboration, while also reducing new discovery partnership activities [25][9] Market Data and Key Metrics Changes - The company is focusing on the therapeutic areas of oncology, neurology, and immunology, which reflect the broader industry activity [35] - The total addressable market for the lead program ABCL635 is estimated to be at least $2 billion in annual sales, while the atopic dermatitis market for ABCL575 is already over $10 billion [17][20] Company Strategy and Development Direction - The company is transitioning from a platform and partnership model to a clinical-stage biotech, with a focus on building an internal pipeline and reducing new discovery partnerships [7][61] - The strategic focus includes selecting programs based on unmet needs, commercial opportunities, differentiation, and clear development paths [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's liquidity position, with over $800 million available to execute its strategy [10][43] - The company plans to initiate Phase 1 clinical trials for its lead programs in 2025 and expects to complete its transition to a clinical-stage biotech [27][24] Other Important Information - The company has completed its move to a new headquarters and is on track to bring its clinical manufacturing facility online in 2025 [9] - The company has received commitments for funding from the Government of Canada's Strategic Innovation Fund and the government of British Columbia, which will support its GMP facility and internal pipeline advancements [42] Q&A Session Summary Question: What competencies are needed for clinical trials across multiple disease areas? - Management stated that they are building up translational science and clinical development teams to support their first two programs moving into clinical development [47][48] Question: Is there a finite number of candidates under the AbbVie collaboration? - Management confirmed that they are excited about the collaboration and are working on multiple but a small number of targets [54] Question: What is the attrition rate for partner-initiated programs? - Management indicated that the attrition rate is consistent with expectations, with over half of the programs still progressing after being handed back to partners [60] Question: Why reduce the number of partnerships pursued? - Management explained that the transition to a clinical-stage biotech necessitated a focus on internal programs, while still seeking opportunities in TCE collaborations [62] Question: What preparations are being made for the upcoming CTA filings? - Management confirmed that extensive preparations have been made for both programs, with no noteworthy special considerations at this time [83]

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Nathan Treybeck - Wells Fargo Danny Stauder - Citizens JMP Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Welcome to the LeMaitre Vascular Q4 202 ...

Compass Diversified (NYSE:CODI) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Cody Slach - Senior MD & Director of Investor Relation Elias Sabo - Partner & CEO Patrick Maciariello - Partner & COO Stephen Keller - Executive Vice President & CFO Conference Call Participants Lawrence Solow - CJS Securities Lance Vitanza - TD Cowen Joseph Reagor - ROTH Capital Randolph Binner - B. Riley Securities Operator Good afternoon, and welcome to Compass Diversified's Fourth Quarter a ...

Amphastar Pharmaceuticals (AMPH) Q4 2024 Earnings Call February 28, 2025 12:12 AM ET Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate CommunicationBill Peters - CFO, Treasurer, EVP - Finance & President of IMS, Ltd., & DirectorJason Gerberry - MD & Equity ResearchCerena Chen - VP - Biotech and Pharma Equity ResearchTony Marrs - Executive VP of Regulatory Affairs & Clinical Operations Conference Call Participants Ekaterina Knyazkova - AnalystDavid Amsellem - Sr. Resear ...

Arlo Technologies, Inc. (NYSE:ARLO) Q4 2024 Earnings Call Transcript February 27, 2025 5:00 PM ET Company Participants Tahmin Clarke - Investor Relations Matthew McRae - Chief Executive Officer Kurt Binder - Chief Financial Officer and Chief Operating Officer Conference Call Participants Adam Tindle - Raymond James Jacob Stephan - Lake Street Hamed Khorsand - BWS Financial Scott Searle - Roth MKM Operator Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mo ...

Financial Data and Key Metrics Changes - In Q4 2024, adjusted EBITDA was reported at $237 million, with distributable cash flow of $155 million and free cash flow of $32 million [19] - For the full year 2024, adjusted EBITDA reached $971 million, representing a 16% year-over-year increase, and capital expenditures totaled $265 million, which was $15 million below the midpoint of guidance [12][24] - The company exited 2024 with a leverage ratio of 3.4 times, down 0.6 times year-over-year [25] Business Line Data and Key Metrics Changes - The Midstream Logistics segment generated adjusted EBITDA of $150 million in Q4, up 3% year-over-year but down 14% sequentially due to negative Waha gas prices impacting volumes [20] - The pipeline transportation segment reported adjusted EBITDA of $92 million, up nearly 9% year-over-year, driven by volume growth and contributions from recent expansions [23] Market Data and Key Metrics Changes - Average gas processed volumes for 2024 were 1.64 billion cubic feet per day, up 13% year-over-year [11] - The company anticipates a 20% growth in gas processed volumes across the system in 2025, outpacing broader Permian growth [26] Company Strategy and Development Direction - The company aims to become a market leader in the Northern Delaware Basin, with strategic M&A and organic growth as key components of its strategy [6] - Kinetik is exploring a large-scale gas-fired power generation facility to manage electricity costs and capitalize on natural gas price volatility [15][16] - The company has set an internal target of achieving $2 billion in EBITDA by 2030, with a focus on organic growth and disciplined capital deployment [54][56] Management's Comments on Operating Environment and Future Outlook - Management noted that 2024 was transformational, with significant milestones in capital allocation and operational performance rebounding by late December [5][11] - The company expects continued growth driven by the Permian supply and US Gulf Coast demand, with LNG exports projected to double by 2030 [13][14] - Management expressed confidence in executing growth strategies and maintaining financial flexibility to pursue both organic and inorganic opportunities [97][98] Other Important Information - The company increased its cash dividend by 4%, marking the first return of capital to shareholders [9] - Kinetik was placed on a positive outlook by S&P, reflecting confidence in its growth trajectory [9] Q&A Session Summary Question: What is the execution risk associated with achieving the 10% EBITDA CAGR target? - Management indicated that they have a strong market share performance and are confident in their ability to execute on growth opportunities, particularly with the King's Landing project [38][39] Question: Are there opportunities for M&A in 2025? - Management acknowledged that while there are opportunities, they maintain a high bar for attractiveness in potential transactions [45][46] Question: How does the company plan to achieve its long-term growth targets? - Management emphasized a focus on organic growth and internal capabilities, with King's Landing being a key project for future growth [56][57] Question: What is the outlook for producer customer activity in 2025? - Management noted robust activity levels among producers, particularly in New Mexico, and highlighted the potential for increased drilling activity if gas prices improve [64][66] Question: How does the company view the competitive landscape for sour gas opportunities? - Management sees significant opportunities in sour gas processing in Northern Delaware and is focused on capitalizing on existing capacity [119] Question: What is the relationship between EBITDA growth and dividend growth? - Management stated that they are prioritizing financial flexibility and retaining cash for growth opportunities, which may result in slower dividend growth [97][98]

Financial Data and Key Metrics Changes - In Q4 2024, adjusted revenue increased by 25% year-over-year, while adjusted EBITDA rose by 70%, with over 200 basis points of margin expansion [8][15] - Non-GAAP EPS for the quarter was $0.40, reflecting a 190% increase from the previous year [15] Business Line Data and Key Metrics Changes - The Consumer Services segment faced pressure due to secular headwinds in the retail channel, but active accounts and revenue declines have eased, aided by a new partnership with PLS [17][18] - The B2B segment continued to drive revenue growth, particularly from a significant BaaS partner, with key metrics such as purchase volume and active accounts increasing [20][21] - The Money Movement segment saw revenue growth in the tax processing business, while cash transfer volumes increased due to new partners [25][26] Market Data and Key Metrics Changes - The overall active accounts increased year-over-year, marking the first quarter of growth in almost four years [9] - The Consumer segment is expected to decline by mid-single digits in the first three quarters of 2025, with a further decline in the fourth quarter due to secular headwinds [29][30] Company Strategy and Development Direction - The company focuses on three strategic pillars: investing in compliance and risk management, improving cost structure, and building stable revenue growth [11][48] - The introduction of the embedded finance brand, Arc by Green Dot, is part of the strategy to enhance service offerings and capitalize on market opportunities [10][39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the B2B and Money Movement segments, despite anticipated declines in the Consumer segment [12][33] - The company plans to continue investing in platform features and functionality to reduce declines in the Consumer segment while pursuing niche opportunities [34][35] Other Important Information - The company anticipates non-GAAP revenue of $1.85 billion to $1.9 billion for 2025, with adjusted EBITDA expected to be between $145 million and $155 million [12][28] - The corporate segment plans to reposition its investment portfolio into higher-yielding floating rate assets, which is expected to generate approximately $10 million in revenue growth [31] Q&A Session Summary Question: Magnitude of macro pressure in 2025 guidance - Management indicated that the guidance considers potential macroeconomic factors, including inflation and yield curve changes affecting interest income [56] Question: Building blocks for margin recovery in Consumer Services and B2B segments - Management discussed focusing on financial service centers to improve direct deposit penetration and optimizing the cost structure to enhance margins [61][64] Question: Opportunities from partnerships and competitive landscape - Management noted a mix of competitive takeaways and greenfield opportunities in their pipeline, with a strong focus on compliance and risk management [73][76] Question: Growth in deposit base and its impact on revenue - The deposit growth is primarily driven by the B2B segment, with expectations for continued growth from new and existing partners [80] Question: Impact of blocked accounts on active growth - Blocked accounts in the Consumer business had a neutral impact on the P&L, as they do not significantly contribute to revenue [88] Question: Regulatory environment and its impact on business - Management emphasized that partners are increasingly diligent regarding compliance, and the company maintains a strong relationship with regulators [92][102] Question: Investments in GO2bank and future features - The company plans to upgrade the user experience for GO2bank and explore new capabilities akin to a marketplace in the future [107][108]